EE124 Cost-Effectiveness Analysis of Dolutegravir/Lamivudine (DTG/3TC) Versus Elvitegravir/Cobicistat/Tenofovir Alafenamide/Emtricitabine (EVG/C/TAF/FTC) for HIV-1 Infection Management in Treatment-Experienced Patients in China
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.427
https://www.valueinhealthjournal.com/article/S1098-3015(23)00527-2/fulltext
Title :
EE124 Cost-Effectiveness Analysis of Dolutegravir/Lamivudine (DTG/3TC) Versus Elvitegravir/Cobicistat/Tenofovir Alafenamide/Emtricitabine (EVG/C/TAF/FTC) for HIV-1 Infection Management in Treatment-Experienced Patients in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00527-2&doi=10.1016/j.jval.2023.03.427
First page :
Section Title :
Open access? :
No
Section Order :
11814